Ipamorelin
Highly selective pentapeptide ghrelin receptor agonist stimulating growth hormone output.
Open Ipamorelin in the 3D analyzerAnalytical specification
| Empirical formula | C38H49N9O5 |
|---|---|
| Molecular weight | 711.9 g/mol |
| Isoelectric point (pI) | 9.50 |
| Assay purity (HPLC) | 99.80% |
| Retention time | 4.90 min |
| Peak area / height | 11200 / 980 |
| Reference batch | IP-2026-V11 |
| Research category | Metabolic & Weight Management |
| Amino-acid sequence | Aib-H-D-2Nal-F-K-NH2 |
Research characteristics
Selective Output
Does not elevate cortisol or prolactin
Ghrelin Agonism
Specifically binds GHS-R1a receptors
Cell Satiety
Fosters clean recovery environments
Nitrogen Balance
Maintains high intra-cellular protein
Reconstitution
Use the interactive reconstitution calculator to convert vial size (mg), bacteriostatic water volume (ml) and target dose (mcg) into a syringe draw on a standard 100-unit insulin syringe. Open the dosage calculator.
Related metabolic & weight management compounds
Retatrutide (Reta)
Next-generation triple receptor agonist (GLP-1, GIP, GCGR) driving advanced metabolic homeostasis.
Tirzepatide (Tirze)
Dual GIP and GLP-1 receptor agonist targeting glucose homeostasis and body composition dynamics.
Semaglutide
Established GLP-1 receptor agonist mimicking natural incretin hormones with modified clearance curves.
Liraglutide
Acylated human glucagon-like peptide-1 analog designed for clinical metabolic investigation models.
Cagrilintide
Long-acting amylin analogue targeting dual pathways in conjunction with incretin receptor systems.
Mazdutide
Novel dual GLP-1R/GCGR agonist targeting lipid elimination and cellular thermodynamic burn.